期刊文献+

16例血液系统恶性肿瘤并发急性肿瘤溶解综合征的临床分析 被引量:13

下载PDF
导出
摘要 目的探讨急性肿瘤溶解综合征(ATLS)在血液系统恶性肿瘤的发生、临床表现、治疗及预后。方法回顾性分析16例血液系统恶性肿瘤并ATLS的临床资料。结果 ATLS易发生在肿瘤负荷高、对化疗敏感的急性淋巴细胞白血病和淋巴瘤患者,常发生于肿瘤化疗后,亦有自发性ATLS发生,主要表现为高尿酸血症、高钾血症、高磷血症、低钙血症,可出现肾功能不全。用别嘌呤醇抑制尿酸合成、碱化尿液、水化,必要时血液透析治疗,15例患者获得较好疗效,1例未治死亡。结论在血液系统恶性肿瘤患者治疗中需注意ATLS的防治,及时诊治,患者可获得较好的预后。
出处 《重庆医学》 CAS CSCD 北大核心 2013年第20期2403-2405,共3页 Chongqing medicine
  • 相关文献

参考文献13

  • 1刘忠文,郭建民,杨靖,张茵,张鲁芳.急性髓性白血病并发肿瘤溶解综合征[J].中华实用诊断与治疗杂志,2010,24(3):247-249. 被引量:7
  • 2Cairo MS.Coiffier B.Reiter Av e; al. Recommendations for the e-valuation of risk and prophylaxis of tumor lysis syn?drornet.TL'S) inadults and children with malignant disea?ses: an expert TLS panel consensus[J]. BrJ Haematol , 2010.149(2) :578-586.
  • 3张佳佳,钟玉萍,陈世伦.硼替佐米治疗多发性骨髓瘤导致急性肿瘤溶解综合征3例[J].中国新药杂志,2009,18(15):1476-1478. 被引量:2
  • 4Abou Mourad Yv Taller Av Shamseddine A. Acute tumorl?ysis syndrome in larse B-cell non- Hodgkin lymphoma in?duced by steroids and anti-CD20[J]. HematolJ. 2003. 4 (3): 222-224.
  • 5陈净,李剑.利妥昔单抗的罕见不良反应[J].药物不良反应杂志,2010,12(5):321-324. 被引量:17
  • 6刘济轩,郭智,谭晓华,陆宁宁,楼金星,陈霞.美罗华治疗非霍奇金淋巴瘤致急性肿瘤溶解综合征1例报道并文献复习[J].中华实用诊断与治疗杂志,2009,23(10):1009-1010. 被引量:6
  • 7. Hande KR, Garrow GC. Acute tumor lysis syndrome in patients with high-grade non- Hodgkins lymphoma[J]. AmJ Med, 1993,94(2): 133-139.
  • 8Cairo MS, Bishop M. Tumour lysis syndrome: new thera?peutic strategies and classification[J]. BrJ Haematol, 2004,1270) :3-11.
  • 9HochbergJ, Cairo MS. Tumor lysis syndrome: cunent per?spective[J]. Haematologica,2008,930) :9-13.
  • 10Will A. Tholouli E. The clinical management of tumor ly?sis syn-drome in haematological malignancies[J]. BrJ Haematol, 2011,1540) : 3-13.

二级参考文献54

  • 1孟光丽,方玉琴,卫好国.自发性实体肿瘤溶解综合征1例报告及文献复习[J].肿瘤研究与临床,2004,16(3):199-200. 被引量:2
  • 2邹海萍,郭晔.利妥昔单抗导致的骨髓抑制及急性肿瘤溶解综合征1例[J].中国癌症杂志,2007,17(5):406-407. 被引量:5
  • 3MA MH,YANG HH,PARKER K,et al. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotberapeutic agents [ J ]. Clin Cancer Res, 2003,9 (3) :1136 - 1144.
  • 4Millennium Pharmaceuticals, Inc. VelcadeTM (bortezomib) for injection[ R]. Prescribing information. Cambridge, MA: Millennium Pharmaceuticals, Inc. , 2004.
  • 5LONIAL S, WALLER EK, RICHARDSON PG, et al. Evaluation of the degree of thrombocytopenia and associated risk factors following bortezomib therapy for relapsed multiple myeloma [ J ]. Blood,2003,102:447 a.
  • 6KENEALY MK, PRINCE HM,HUNEMANN D,et al. Tumor lysis syndrome early after treatment with bortezomib for multiple myeloma[ J ]. Pharmacotherapy,2006,26 (8) : 1205 - 1206.
  • 7JESuS S M, JOAN B, MARIO B. et al. A practical update on the use of bortezomib in the management of multiple myeloma[ J]. The Oncologist, 2006,11 ( 1 ) :51 - 61.
  • 8Cairo M S, Bishop M. Tumor lysis syndrome: new therapeutic strategies and classification[J]. Br J Haematol,2001,127(1):3- 11.
  • 9Otrock Z K, Hatoum H A, Salem Z M. et al. Acute tumor lysis syndrome after rituximab administration in Burkitt's lymphoma [J]. Intern Emerg Med.2008.3(2):161-163.
  • 10Fleming D R. Doukas M A. Acute lumor lysis syndrome in hematologic malignancies [J]. Leuk Lymphoma. 1992,8(4-5): 315-318.

共引文献32

同被引文献91

引证文献13

二级引证文献29

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部